25 patents
Utility
Compositions and Methods for Treating Hematopoietic Malignancy
4 Jan 24
Aspects of the disclosure provide methods and compositions for treating a hematopoietic malignancy (e.g., acute myeloid leukemia).
Christopher Slapak, Glen Raffel, Michelle Lin, John Lydeard, Tirtha Chakraborty
Filed: 27 Oct 21
Utility
Methods and Compositions Relating to Genetically Engineered Cells Expressing Chimeric Antigen Receptors
28 Dec 23
The disclosure is directed to methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors, where the cells are mobilized lymphocytes.
Sadik Kassim, Julian Scherer, Giacomo Canesin, Tirtha Chakraborty
Filed: 12 Nov 21
Utility
Compositions and Methods for CD38 Modification
14 Dec 23
Provided herein are gRNA comprising a targeting domain that targets CD38, which may be used, for example, to make modifications in cells.
John Lydeard, Mark Jones, Michael Pettiglio, Tirtha Chakraborty
Filed: 14 Sep 21
Utility
Chimeric Antigen Receptors for Treatment of Cancer
23 Nov 23
Provided are chimeric antigen receptors (CARs) with binding specificity for CD33.
Sadik Kassim, Julian Scherer
Filed: 14 Sep 21
Utility
Single Domain Antibodies Against CD33
16 Nov 23
The present disclosure includes antibodies that specifically CD33, as well as methods of making and using such antibodies.
Sadik Kassim, Julian Scherer
Filed: 14 Sep 21
Utility
Chimeric Antigen Receptor Expression Systems
16 Nov 23
Aspects of this disclosure provide nucleic acid constructs A nucleic acid construct, comprising a first expression cassette comprising a nucleic acid encoding a tetracycline-responsive transactivator under the control of a cell type-specific promoter; and a second expression cassette comprising a nucleic acid encoding a transgene, for example, a chimeric antigen receptor (CAR), under the control of a tetracycline-responsive promoter.
Sadik Kassim, Tirtha Chakraborty, Julian Scherer
Filed: 30 Sep 21
Utility
Compositions and Methods for CD30 Gene Modification
16 Nov 23
Provided herein are gRNA comprising a targeting domain that targets CD30, which may be used, for example, to make modifications in cells.
John Lydeard, Mark Jones, Michael Pettiglio, Tirtha Chakraborty
Filed: 30 Sep 21
Utility
Compositions and Methods for CD6 Modification
16 Nov 23
Provided herein are gRNA comprising a targeting domain that targets CD6, which may be used, for example, to make modifications in cells.
John Lydeard, Mark Jones, Michael Pettiglio, Tirtha Chakraborty
Filed: 28 Sep 21
Utility
Genetically Engineered Hematopoietic Stem Cells and Uses Thereof
16 Feb 23
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Filed: 31 May 22
Utility
Genetically engineered hematopoietic stem cells and uses thereof
7 Feb 23
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Filed: 5 Apr 21
Utility
Genetically engineered hematopoietic stem cells and uses thereof
24 Jan 23
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Filed: 5 Apr 21
Utility
Compositions and Methods for CD123 Modification
20 Oct 22
This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CD123 gene.
John Lydeard, Chonh Luo, Bibhu Prasad Mishra, Michelle Lin
Filed: 28 Aug 20
Utility
Genetically engineered hematopoietic stem cells and uses thereof
11 Oct 22
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Filed: 5 Apr 21
Utility
Compositions and Methods for CLL1 Modification
15 Sep 22
This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CLL1 gene.
John Lydeard, Chong Luo, Michelle Lin
Filed: 28 Aug 20
Utility
Compositions and Methods for CD33 Modification
21 Jul 22
Some aspects of this disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CD33 gene.
John Lydeard, Bibhu Prasad Mishra
Filed: 22 May 20
Utility
Genetically engineered hematopoietic stem cells and uses thereof
19 Jul 22
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Filed: 28 Aug 19
Utility
Genetically engineered hematopoietic stem cells and uses thereof
12 Jul 22
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Filed: 5 Apr 21
Utility
Genetically Engineered Hematopoietic Stem Cells and Uses Thereof
13 Jan 22
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Filed: 16 Feb 21
Utility
Genetically Engineered Hematopoietic Stem Cells and Uses Thereof
14 Oct 21
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Filed: 5 Apr 21
Utility
Genetically Engineered Hematopoietic Stem Cells and Uses Thereof
5 Aug 21
Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.
Joseph Bolen, Aleksandar Filip Radovic-Moreno, John Lydeard
Filed: 5 Apr 21